cytes. Also, Meg-Pot increases the number of megakaryocyte colonies induced by Meg-CSF. 16 To date, cytokines such as erythr~poietin,'~ GM-CSF,18 IL-l,'5J9 IL-6,20 and IL-1lZ1 have been shown to exhibit Meg-Pot activity.
In the present study, we detected thrombocytosis in the majority of patients with CSF-producing tumors, and examined whether Meg-CSF or Meg-Pot activity existed in their plasma or in tumor cell culture supernatants, and then identified the cytokines responsible for such activity.
MATERIALS AND METHODS
Fourteen patients with malignant tumors were examined in this study (Table 1) . These patients were referred to our institution from 1986 to 1991 with marked and unexplained leukocytosis ( > 15 x 109/L). None of the patients had been treated with antitumor agents or by irradiation before the study. Bacteriologic examinations, including cultures of blood, urine, sputum, pleural fluid and ascites, chest X-ray, abdominal echography, and computed tomography, gave nonspecific results. Patients 4 through 9, 13, and 14 underwent autopsy, which also showed no major bacterial or fungal infections that could explain their persistent leukocytosis. During the course, five patients received chemotherapy or radiotherapy. Patient 1 was treated with cisplatin. Patient 3 was treated with prednisolone, doxorubicin, cyclophosphamide, and vincristine. Patient 4 was treated with betamethasone, cyclophosphamide, and vincristine. Patient 5 was treated with irradiation to the neck tumor. Patient 10 was treated with irradiation to the maxillary tumor. Response to the chemotherapy in patient 1 and that to the radiotherapy in patient 5 was very poor, and further treatment was not performed. Patients 3 and 4 responded well; however, the lymphomas recurred rapidly, and further treatment was not performed. In patients 1,3, and 4, white blood cell (WBC) and platelet counts decreased after chemotherapy, but soon returned to the level before the therapy. Patient 10 showed complete response to the radiotherapy, and WBC and platelet counts were normalized after the therapy.
Specimens for demonstration of CSF, IL-1, and IL-6 activity.
Plasma was collected from the patients before treatment, filtered through a 0.45-pm membrane filter (Corning, Corning, NY), and stored at -20°C until examination. Tumor cell lines were established from patients 2 and 12 (ascites), and from patients 1 (HTC/C3):2 6 (KHC287): and 11 (pleural fluid). These five patients were in the terminal stage when the samples for tumor cell culture were obtained. Tumor cells from each cell line were cultured in RPMI 1640 (Nissui, Tokyo, Japan) with fetal calf serum (FCS; Hyclone, Logan, UT) for 4 days at an initial density of 2 x Patients. 
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Thyroid carcinoma lo5 cells/mL, and then the culture supernatants were collected. Biopsy specimens were obtained before treatment from patients 3 and 4 (lymph node) and from patients 5 and 10 (tumor tissue). Plastic adherent cell-depleted (incubation for 2 hours at 37°C in 5% CO2) mononuclear cells (NAC) were separated from these specimens. All the biopsy specimens were shown to be composed almost completely of tumor tissue by histologic examination. The cells obtained from the biopsies were cultured for 1 week in RPMI 1640 with 10% FCS at a initial density of 5 x lo5 cells/mL, and then the culture supernatants were stored at -20°C. As a control for the culture supernatants of lymphoma cells (patients 3 and 4), NAC from lymph nodes diagnosed as chronic lymphadenitis were cultured in the same way, after informed consent was obtained to collect the samples. As a control for the culture supernatant of cells obtained from tumor masses (patients 5 and lo), fibroblasts separated from the control lymph node samples were used. After two subcultures, these fibroblasts were cultured for 7 days at an initial density of 5 x lo5 cells/mL.
Assay of granulocyte-macrophage progenitors (CFU-GM). Bone marrow (BM) cells were obtained with informed consent from patients with possible early lymphoma as part of the process of clinical staging. The CFU-GM assay used has been described previously.' Briefly, plastic nonadherent BM mononuclear cells (BM-NAC; 2 x 1@/mL) were mixed with Iscove's modified Dulbecco's minimal essential medium (IMDM; GIBCO, Grand Island, NY), the test specimen (either culture supernatant or plasma) at 5% to 30%, 20% FCS, and 0.9% methylcellulose (Dow Chemicals, Quebec, Canada). When the test specimen was plasma, the concentration of FCS was reduced to 5%. Aliquots of this mixture (0.5 mL) were cultured in 24-well microplates (Corning) for 14 days at 37°C in 5% COz, and colonies containing more than 50 granulocytes were counted using an inverted microscope (Olympus, Tokyo, Japan). In some experiments, clusters of 10 to 49 granulocytes were scored.
The assay for CFU-Meg was performed as described p r e v i o~s l y .~~ In brief, T-cell-depleted BM-NAC (1 x lo5/ mL) were mixed with IMDM, 30% human plasma from a healthy donor (normal plasma), 5% FCS, 5 x mol/L 2-mercaptoethano1 (2ME; Sigma, St Louis, MO), 50 U/mL of recombinant IL-3 (rIL-3; Genzyme, Boston, MA), and 0.9% methylcellulose. Aliquots of this mixture (1 mL) were cultured in 35 x 12 mm plastic dishes (Lux, Naperville, IL) at 37°C in 5% Con. On day 14 of culture, megakaryocyte colonies (aggregates of > 8 megakaryoAssay of CFU-Meg. cytes) were counted using an inverted microscope. Using this as the basic culture method, the Meg-CSF or Meg-Pot activity of specimens was tested.
Specimens from the patients were treated with anti-G-CSF, anti-GM-CSF, or anti-IL-6 monoclonal antibodies (MoAbs) for 30 minutes at room temperature, at 25 pg/mL, 5 pg/mL, and 20 pg/mL of protein (antibody) concentration, respectively, and were then added to the culture cocktails of the CFU-GM or CFU-Meg assays. The anti-granulocyte-CSF (anti-G-CSF) and anti-IL-6 (MH166)U MoAbs were kindly provided by Chugai Pharmaceutical Co (Tokyo, Japan), and 10 pg of these two antibodies can completely neutralize the biologic activity of 50 ng of human G-CSF and that of 10 ng of human IL-6, respectively. The anti-GM-CSP MoAb was purchased from Genzyme, and 10 pg of which can completely neutralize the biologic activity of 10 ng of human GM-CSF. In our preliminary experiments, these three antibodies did not affect colony formation of erythroid progenitors (CFU-E) at their respective concentrations used in the present study, indicating that there was no nonspecific toxicity of these antibodies.
The G-CSF concentration was measured by ELISA as described p r e v i o~s l y .~~ The Assay Technology Research Center of Chugai Pharmaceutical Co performed this ELISA. GM-CSF, IL-la, IL-lp, and IL-6 concentrations were measured using ELISA kits purchased from Genzyme Co (GM-CSF and IL-6) and Ohtsuka Pharmaceutical Co (Tokyo, Japan) (IL-la and IL-1p). The concentration of the tumor necrosis factor a (TNFa) was measured by an ELISA kit purchased from Ohtsuka Pharmaceutical Co.
Transplantation of a CSF-producing cell line into nude mice. Cells (5 X lo6) from a tumor cell line (KHC287) derived from patient 6 were injected subcutaneously into nude mice (BALB/c, nulnu). The tumor size, WBC count, and platelet count were measured weekly.
Statistical significance was evaluated using the Student's t-test.
Antibody neutraluation of colony formation.

Enzyme-linked immunosorbent assay (ELISA).
Statistical analysis. Table 1 shows the clinical and hematologic data of the 14 patients examined. All patients had advanced tumors. None of them had splenomegaly, except for patient 4, who had an immunoblastic lymphade-
RESULTS
Hematologic findings.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From nopathy (1BL)-like T lymphoma. Serum C-reactive protein (CRP) levels were remarkably high in the majority of the patients. Fibrinogen concentrations were also elevated in proportion to the CRP levels in individual patients. All patients (except for patients 2 and 11) had spiking fever of greater than 38°C every day or once every few days. Leukocytosis was neutrophil-dominant, and no immature granulocytes or erythroblasts were seen. Leukocyte alkaline phosphatase activity was high in all patients (data not shown). A BM aspirate showed granulocytic hyperplasia (data not shown), and no dysplastic features of the hematopoietic cells were seen in any of the 14 patients.
Thrombocytosis of greater than 400 x 109/L was noted in 12 patients. Four patients (patients 1, 3, 4, and 13) had GM-CSF-producing tumors and the remaining 10 had G-CSF-producing tumors. Patients with GM-CSF-producing tumors had higher platelet counts than those with G-CSF-producing tumors. The median peak platelet count was 579 x 109/L (range, 526 to 910 X 109/L) for patients with GM-CSF-producing tumors and 511 x 109/L (range, 384 to 694 x 109/L) for patients with G-CSF-producing tumors. However, there was no significant difference in the mean peak platelet count of patients with tumor-producing GM-CSF (648 2 88 x lo9& mean 2 SE) and G-CSF (516 2 34 x 109/L). In most patients, the peak platelet count was observed at the time of admission or when their general condition was stable, and then it declined, even before treatment, towards the terminal stage. In contrast, the WBC count increased progressively, even during the terminal stage, in the majority of the patients. Figure 1 shows the representative clinical course of a patient (patient 9) who did not have any specific treatment. As another example, in patient 5, who had a solitary tumor (malignant fibrous histiocytoma) in the right side of the neck, the highest platelet count was observed at the time of admission, and the count gradually decreased and remained within normal limits in the terminal stage. Meanwhile, the WBC count progressively increased in proportion to the size of the neck tumor even in the terminal stage. Irradiation to the tumor was ineffective and had little effect on the WBC and platelet counts.
Assay of CFU-GM and antibody neutralization of colony formation. All untreated specimens from each patient generated granulocytic colonies in a dose-dependent manner when they were added (five to 30%) to the CFU-GM culture. Table 2 shows representative results in each patient. Addition of 30% plasma from patient 7 did not cause colony formation, but the number of clusters was significantly higher than that obtained when 30% plasma from a healthy donor was added. With plasma from patients 1,3,4, and 13, some eosinophilic clusters (but not colonies) were generated in addition to granulocyte colonies. Colony formation was almost completely suppressed by either anti-G-CSF or anti-GM-CSF MoAb, indicating the presence of either G-CSF or GM-CSF in the specimens. There were no specimens for which colony formation was significantly inhibited by both the anti-G-CSF and anti-GM-CSF MoAbs. The results of this assay indicated that patients 1,3, 4, and 13 had GM-CSF-producing tumors, while the remaining 10 patients had G-CSF-producing tumors.
G-CSF, GM-CSF, IL-1% IL-I@, and IL-6 concentrations in theplasma and culture supernatant. As shown in Table 3 , the G-CSF concentrations were obviously elevated in all specimens, except for those from patients 1,3,4, and 13, for whom the GM-CSF concentrations were high enough to produce colonies.
As shown in Table 4 , the plasma IL-la level was elevated in all nine patients examined, whereas IL-1p was undetectable in any of the plasma samples. IL-6 was also detected in the plasma of all nine patients examined. When tumor cell culture supernatants either from primary cultures or cultures of established cell lines were examined in eight patients, the IL-la and IL-6 concentrations were elevated in all eight patients and IL-1P was detectable in four of eight cases. Similar results concerning the above-mentioned five cytokines were obtained in all these patients when plasma samples taken at different time points were examined. Plasmas from patients 7, 8, 9, 13, and 14, in whom tumor tissues for the culture study were not available, were examined at least three times and gave always same results in the type of CSF (G-CSF or GM-CSF) in each patient (data not shown).
TNFa was not detectable (less than 7 pg/mL) in the culture supernatants of all five cell lines (derived from patients 1, 2, 6, 11, and 12) and in all five plasmas (from patients 5,7,9,10, and 13) examined.
Meg-CSF and Meg-Pot activity in plasma from patients with GM-CSFyroducing tumors. As shown in Table 5 , plasma from patient 3 with a GM-CSF-producing lymphoma caused significant megakaryocyte colony formation when added (30%) to CFU-Meg cultures without exogenous Meg-CSF. This colony formation was abolished by treatment of the plasma with anti-GM-CSF MoAb, indicating that the Meg-CSF activity in the plasma was attributable to GM-CSF. The plasma also produced a significantly (P < 
Data are shown as mean f SE (n = 3). As the control for culture supernatant, the same amount of RPMl 1640 with 10% FCS was added to CFU-GM cultures. As the control for patient plasma, the same amount of normal plasma was used. In patient 7, the number of clusters (10 to 49 granulocytes) was evaluated. *Adherent cell-depleted BM mononuclear cells.
higher number of megakaryocyte colonies in the presence of sufficient IL-3 (50 U/mL) when compared with normal plasma, indicating the presence of Meg-Pot activity in the plasma. Megakaryocyte colony formation by the patient's plasma and IL-3 was significantly decreased (P < .Ol) to reach the control level (normal plasma and IL-3) by the addition of anti-IL-6 MoAb, but not by anti-GM-CSF MoAb. Although the latter antibody also decreased the colony count to some extent, the difference was not significant. Similar results were obtained with plasma from patient 4, who had IBL-like T lymphoma (data not shown).
Meg-CSF and Meg-Pot activity in the culture supernatants of GM-CSF-producing tumors. The culture supernatant of lymphoma cells from patient 3 generated 7.7 f 1.2 (mean f SE; n = 3) megakaryocyte colonies when it was added at 10% to CFU-Meg cultures with 30% normal plasma alone. This colony formation was abolished by anti-GM-CSF MoAb (P < .01). The culture supernatant (10%) also significantly (P < .OS) enhanced megakaryocyte colony formation by normal plasma and IL-3 (from 25.3 ? 2.0 to 40.7 ? 2.4 colonies). This enhancement was not completely abolished by either anti-GM-CSF MoAb (33.3 rf: 2.8) or anti-IL-6 MoAb (31.0 ? 2.7), but was abolished by simultaneous treatment (23.7 f 2.5, P < .02) of the culture supernatant with these two MoAbs. Culture supernatant of the HTC/C3 cell linez2 derived from patient 1 had similar Meg-CSF activity (attributable to GM-CSF) and Meg-Pot activity (due to GM-CSF and IL-6) when specimens were added to CFU-Meg cultures at a concentration of 20% (data not shown).
Plasma Meg-Pot activity in patients with G-CSF-producing tumors. As shown in Table 6 , plasma from patient 9 did not generate megakaryocyte colonies when added at 30% to CFU-Meg cultures without exogenous Meg-CSF. The patient's plasma produced a higher number of megakaryocyte colonies than normal plasma in the presence of sufficient IL-3, although the difference was not significant. However, the increase became significant (P < .05) when the IL-3 concentration was reduced to 25 U/mL. The enhancement of megakaryocyte colony formation by the patient's plasma was abolished by anti-IL-6 MoAb, but not by anti-G-CSF MoAb. The addition of plasma from patient 14 did not in itself induce megakaryocyte colonies. Similar to the plasma from patient 9, the plasma produced a significant (P < .05) increase in megakaryocyte colonies compared with normal plasma only in the presence of a suboptimal dose of IL-3 (25 U/mL) (data not shown). We also examined the Meg-Pot activity in the plasma from patients 5 and 8. The addition of these plasma samples produced a greater number of megakaryocyte colonies in the presence of 25 U/mL IL-3 than normal plasma did, but the difference was not significant (data not shown).
Meg-Pot activity in the culture supernatants of G-CSFproducing tumor cells. The culture supernatant of the KHC287 cell line7 derived from patient 6 did not induce megakaryocyte colony formation when added at 10% to CFU-Meg cultures with 30% normal plasma alone. However, addition (10%) of the supernatant, significantly (P < .05) enhanced colony formation by normal plasma and IL-3 (50 U/mL) (from 20. it was added at 20% to CFU-Meg cultures with 30% normal plasma and 25 U/mL IL-3 (data not shown). Thrombocytosis in nude mice transplanted with a CSFproducing tumor cell line (KHC287). KHC287 derived from patient 6 was successfully transplanted to nude mice where they had formed subcutaneous tumors. As shown in Fig 2, the platelet and WBC counts of the mice increased in proportion to tumor size. The peak platelet and WBC counts were 1,410 x 109/L and 45.5 X 109/L, respectively.
DISCUSSION
A number of investigators have reported thrombocytosis in patients with malignant t~m o r s ,~~-~~ but the cause of such thrombocytosis has remained unclear. Recently, Hollen et a1 described a high serum level of IL-6 in patients with malignant tumors associated with IL-6 has a potent Meg-Pot activity*O and causes thrombocytosis when injected into animals,32 so it appears to be reasonable to attribute the thrombocytosis associated with malignancy to elevated serum IL-6 level. However, Hollen et aI3l did not determine whether the tumors produced IL-6 or whether the patients' serum had Meg-CSF or Meg-Pot activity.
In regard to patients with CSF-producing tumors, there are only a few reports on thrombocytosis without any mention of its c a u~e .~,~ We recently noted coproduction of IL-1 and IL-6 in tumor cell lines elaborating G-CSF or GM-CSF. 8 In the present study, we therefore examined whether thrombocytosis was present in patients with CSFproducing tumors, and noted thrombocytosis of greater than 400 x 109/L in 12 of 14 patients. We then examined whether coproduction of IL-1 and IL-6 occurred in these patients, as had been seen in CSF-producing tumor cell lines. We found a high level of IL-la or IL-6 in the plasma or tumor cell culture supernatants from almost all of the patients. Spiking fever of greater than 38°C and a marked increase of the CRP level were observed in almost all of the patients, clinical manifestations that may, respectively, reflect IL-1 and IL-6 production by their tumors. IL-1 is known to cause fever33 and IL-6 stimulates the production of acute phase proteins by liver cells.34 In 1986, Nakano et a1 reported a positive correlation between the CRP level and the platelet count in patients with malignant mesothelioma associated with thrombocyto~is.~~ The cause of the thrombocytosis was not determined in their study, but the high CRP level might have been due to IL-6 production by these tumors.
We then examined whether Meg-CSF or Meg-Pot activity was present in the plasma or tumor cell culture supernatants from our 14 patients. Meg-CSF activity was found in both plasma samples and tumor cell culture supernatants in < 100
ND
Control specimens were the same as in Table 3 . Concentrations of cytokines were measured by ELISA. The lower limits of detection for IL-la, IL-lp, and IL-6 were 3,15, and 100 pg/mL, respectively.
'Culture supernatants from the same established cell lines mentioned in Table 3 .
For 'T-cell-and adherent cell-depleted BM marrow mononuclear cells. tNormal plasma from a healthy donor.
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the patients with GM-CSF-producing tumors. The Meg-CSF activity was abolished by addition of an anti-GM-CSF MoAb, indicating that GM-CSF was responsible for the Meg-CSF activity in these specimens. Furthermore, these specimens enhanced IL-3-induced megakaryocyte colony formation, indicating the presence of Meg-Pot activity in addition to Meg-CSF activity. The Meg-Pot activity of patient plasma was almost completely abolished by anti-IL-6 MoAb, but not anti-GM-CSF MoAb, indicating that IL-6 was the largest component of this activity. The small amount of Meg-Pot activity attributable to GM-CSF may have been due to the low levels of this CSF in the plasma examined. Similarly, the reason why the plasma samples exhibited definite Meg-CSF activity regardless of their low GM-CSF level may have been the enhancement of the Meg-CSF activity of GM-CSF by the coexistent Meg-Pot activity of IL-6. In contrast to the plasma samples, tumor cell culture supernatants from the patients with GM-CSFproducing tumors had Meg-Pot activity originating from both GM-CSF and IL-6. The concentrations of GM-CSF and IL-6 in these supernatants were higher than those in the plasma samples and these two cytokines appeared to exhibit almost equal Meg-Pot activity. In the patients with G-CSF-producing tumors, neither plasma nor tumor cell culture supernatants had Meg-CSF activity. However, plasma samples and tumor cell culture supernatants from these patients had Meg-Pot activity that was abolished by For personal use only. on August 30, 2017. by guest www.bloodjournal.org From thrombocytosis in patients with G-CSF-producing tumors was due to the Meg-Pot activity of IL-6.
It has been reported that more than one CSF is produced by a few established cell lines.6,s However, in the present study, colony formation was inhibited by only one of the two anti-CSF antibodies. The CSF concentrations determined by ELISA also supported the results obtained by the CFU-GM assay combined with anti-CSF antibodies. It may be difficult to detect minute levels of CSF production with our assay system, but it is likely that the CSFs identified in the present study reflect those mainly produced in the individual patients.
Despite the presence of both Meg-CSF and Meg-Pot activity in patients with GM-CSF-producing tumors, the mean peak platelet counts of these patients were not significantly higher than those of the patients with G-CSFproducing tumors. However, the peak platelet count exceeded 500 x 109/L in all four patients with GM-CSFproducing tumors, and one of them had the highest platelet count (910 x 109/L) among the 14 patients in this study. Two of the 10 patients with G-CSF-producing tumors had a peak platelet count less than 400 x 109/L, and the mean peak platelet count of these 10 patients was lower than that of the four patients with GM-CSF-producing tumors, although the difference was not significant. Thus, it seems possible that patients with GM-CSF-producing tumors develop higher platelet counts than those with G-CSFproducing tumors. However, further studies on a larger number of patients with CSF-producing tumors are required to confirm this.
In the present study, we did not examine the involvement of Meg-Pot activity due to IL-la, because the IL-la levels in the specimens from our patients were less than one-tenth of the concentration (10 U/mL) at which this cytokine exhibits Meg-Pot activity as evaluated by platelet production of megakaryocyte colonies.15 However, IL-1 stimulates BM stromal cells or fibroblasts to produce IL-6,35 so it is likely that any IL-la produced by the tumors of our patients contributed to their thrombocytosis by stimulating the IL-6 production of mesenchymal cells. Indeed, thrombocytosis was described in a clinical trial of IL-lp.36
The reason why the platelet count decreased toward the terminal stage in the majority of our patients is unclear. This may be one reason why thrombocytosis has not been widely noticed in patients with CSF-producing tumors. A possible explanation is that changes in the cytokine production by tumors, especially deterioration of IL-6 production, might have occurred toward the terminal stage. We did not examine the cytokine levels in the plasmas from patients in the terminal stage. However, tumor cell lines derived from five patients in the terminal stage in the present study give us a clue, ie, these five cell lines obviously retained the ability to produce IL-6 or GM-CSF, as well as IL-1 or G-CSF. From this fact, deterioration of IL-6 or GM-CSF production by tumors in the terminal stage may be unlikely. Disseminated intravascular coagulopathy (DIC) or pre-DIC may be another cause of the decline of thrombocytosis, because DIC tends to occur in the terminal stage of various malignant diseases. Furthermore, IL-1 (IL-la and IL-1 p) and TNF can act on cultured human vascular endothelial cells to induce a tissue factor-like procoagulant activity,37 although the latter cytokine was undetectable in the culture supernatants of the established five cell lines or in the five plasmas examined. Also, IL-1 induces vascular endothelial cells to synthesize plasminogen activator Persistent IL-1 production by the tumors, therefore, may be hazardous as the potential inducer of DIC. Indeed, patient 11 developed DIC in the terminal stage. However, in this patient, the platelet count had already started to decrease before the DIC became overt. Another important observation was that, in the majority of the patients, fibrinogen concentrations tended to decline toward the terminal stage, although the levels remained high or normal except for in patient 11. In patients 1, 4, and 5, concentrations of fibrinogen degradation products were slightly elevated regardless of normal fibrinogen levels and platelet counts in the terminal stage. From these facts, pre-DIC should be taken into consideration as the possible cause of the deterioration of thrombocytosis. However, in the present study, hemostatic examinations were not performed sufficiently when the thrombocytosis began to decline or during the time the platelet count remained normal. Thus, in the next series, precise studies on coagulopathy will be required even during the period of thrombocytosis.
